Efficient and Stable Low Iridium Loaded Anodes for PEM Water Electrolysis Made Possible by Nanofiber Interlayers

Significant reduction of the precious metal catalyst loading is one of the key challenges for the commercialization of proton-exchange membrane water electrolyzers. In this work we combine IrOx nanofibers with a conventional nanoparticle-based IrOx anode catalyst layer. With this hybrid design we can reduce the iridium loading by more than 80% while maintaining performance. In spite of an ultralow overall catalyst loading of 0.2 mg(Ir)/cm(2), a cell with a hybrid layer shows similar performance compared to a state-of-the-art cell with a catalyst loading of 1.2 mg(Ir)/cm(2) and clearly outperforms identically loaded reference cells with pure IrOx nanoparticle and pure nanofiber anodes. The improved performance is attributed to a combination of good electric contact and high porosity of the IrOx nanofibers with high surface area of the IrOx nanoparticles. Besides the improved performance, the hybrid layer also shows better stability in a potential cycling and a 150 h constant current test compared to an identically loaded nanoparticle reference.BMBF, 05KI9VFA, Ultrahochauflösende Untersuchung des Wassertransports in alkalischen Brennstoff- und Elektrolysezellen mittels Neutronenradiographie und –Tomographie (NeutroSense

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis

OBJECTIVE: To determine the prevalence of antibodies to Epstein-Barr virus (EBV) in a large cohort of patients with early multiple sclerosis (MS). METHODS: Serum samples were collected from 901 patients with a clinically isolated syndrome (CIS) or early relapsing-remitting multiple sclerosis (RRMS) participating in the German National MS cohort, a prospective cohort of patients with early MS with stringent inclusion criteria. Epstein-Barr nuclear antigen (EBNA)-1 and viral capsid antigen (VCA) antibodies were measured in diluted sera by chemiluminescence immunoassays (CLIAs). Sera of EBNA-1 and VCA antibody-negative patients were retested undiluted by an EBV IgG immunoblot. For comparison, we retrospectively analysed the EBV seroprevalence across different age cohorts, ranging from 0 to >80 years, in a large hospital population (N=16 163) from Berlin/Northern Germany. RESULTS: EBNA-1 antibodies were detected by CLIA in 839 of 901 patients with CIS/RRMS. Of the 62 patients without EBNA-1 antibodies, 45 had antibodies to VCA as detected by CLIA. In all of the remaining 17 patients, antibodies to EBV were detected by immunoblot. Altogether, 901 of 901 (100%) patients with CIS/RRMS were EBV-seropositive. EBV seropositivity increased with age in the hospital population but did not reach 100% in any of the investigated age cohorts. CONCLUSION: The complete EBV seropositivity in this large cohort of patients with early MS strengthens the evidence for a role of EBV in MS. It also suggests that a negative EBV serology in patients with suspected inflammatory central nervous system disease should alert clinicians to consider diagnoses other than MS

Treatment choices and neuropsychological symptoms of a large cohort of early MS

Objective To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS. Methods The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms. Results Of 1,124 patients, with a 2.2: 1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively. Conclusion Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients

Ciguatera or why you should enquire about fish consumption in cases of cold allodynia

Ciguatoxins (CTX) are potent marine biotoxins produced by microalgae, which may accumulate seasonally, and which are locally variable in tropical predatory fish. Gastrointestinal, neurologic and/or cardiovascular symptoms occur shortly after the consumption of fish. Due to the high affinity of CTX to neuronal sodium channels, neurologic symptoms constitute a hallmark of ciguatera fish poisoning (CFP). Almost pathognomonic for CFP is an alteration of temperature perception (cold allodynia), in which cold surfaces are perceived as hot, painful, or produce dysesthesia (unpleasant, abnormal sensation). Increasing imports of tropical fish have led to more frequent reports of ciguatera in temperate climatic zones. We illustrate the specific features of CFP by reporting two cases due to imported tropical fish